Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03449901 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer | completed | Phase 2 | 98 | Washington University School of MedicineOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05235100 | Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma (SPARE-02)(SPARE-02) | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| 1 |
| Dec 11, 2025 |
| clinicaltrials |
| NCT05938374 | Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)(SPARE-03) | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06128863 | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial(EFTISARC-NEO) | active not recruiting | Phase 2 | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03725605 | LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) | completed | Phase 2 | 6 | Lytix Biopharma ASINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors(Briga-PED) | recruiting | Phase 1 / Phase 2 | 65 | Princess Maxima Center for Pediatric OncologyOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT01991379 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 1 / Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06939855 | QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04551430 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | active not recruiting | Phase 2 | 105 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT06208748 | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | active not recruiting | Phase 2 | 40 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05886634 | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02285439 | Study of MEK162 for Children With Low-Grade Gliomas | completed | Phase 1 / Phase 2 | 105 | Children's Hospital Los AngelesOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05182164 | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas(PEMBROCABOSARC) | recruiting | Phase 2 | 119 | Institut BergoniéOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07205185 | A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma. | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Oct 3, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03425279 | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | completed | Phase 1 / Phase 2 | 245 | BioAtla, Inc.INDUSTRY | 3 | Sep 23, 2025 | clinicaltrials |
| NCT04258956 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy(AXAGIST) | completed | Phase 2 | 58 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05366816 | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | recruiting | Phase 2 | 48 | University of MiamiOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07156643 | A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. | not yet recruiting | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(CYCLIGIST) | completed | Phase 2 | 29 | Institut BergoniéOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT04776525 | Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | recruiting | Phase 2 | 49 | Oslo University HospitalOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05385549 | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | recruiting | Phase 2 | 35 | Asan Medical CenterOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT01979393 | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | completed | Phase 2 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Aug 1, 2025 | clinicaltrials |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy | terminated | Phase 2 | 110 | Washington University School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06772233 | A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment | not yet recruiting | Phase 2 | 100 | Peking UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06367075 | A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 53 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05679921 | Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma | recruiting | Phase 2 | 116 | Yonsei UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07067255 | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer(BAH2573-104) | recruiting | Phase 1 / Phase 2 | 80 | Essen BiotechOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06114004 | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)(SeliSarc) | recruiting | Phase 2 | 88 | Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03951571 | Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma | completed | Phase 2 | 88 | Fudan UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00742963 | Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 107 | ImmunoGenesisINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05894018 | Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma(RAFAS-001) | recruiting | Phase 2 | 32 | Fujun ZhangOTHER | 1 | May 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials